Immunotherapy Combinations Deliver Outcome-Shifting Responses in Lymphoma
Immunotherapy has become a valuable tool for the treatment of patients with various types of lymphomas because of its ability to specifically target cancer cells, particularly those in blood cancers.
Deeper Understanding of immune System Could Advance Treatment Options in Lymphoma
Stephen M. Ansell, MD, PhD, discusses the successes and challenges of utilizing immune therapy across the landscape of hematologic malignancies, the importance of increasing the understanding of how the immune system functions in patients with lymphoma, and ongoing research of immune therapy for this patient population.
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
September 25th 2023The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
Although findings from the International Duration Evaluation of Adjuvant Therapy collaboration in 2018 failed to demonstrate the noninferiority of 3 months of adjuvant chemotherapy vs 6 months for patients with stage III colon cancer, clinically relevant data in subgroup analyses have influenced practice prescribing patterns, according to a retrospective analysis.
Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
September 11th 2023Dr Fonkoua discusses the ways in which common clinical trial enrollment criteria in oncology exclude patients from underrepresented groups, enrollment disparities that uniquely affect patients with liver cancer, and initiatives that Mayo Clinic is participating in to eliminate barriers to clinical trial enrollment.
Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel
September 7th 2023Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.
Dr Fonkoua on the Effects of the Platinum Chemotherapy Shortage on Disparities in Cancer Care
August 18th 2023Lionel A. Kankeu Fonkoua, MD, discusses how the platinum chemotherapy shortage in the United States may exacerbate disparities in cancer care and the importance of conducting research to investigate the potential implications of this shortage on patients in underserved communities.
Novel Treatment Approaches for SCLC and Future Perspectives
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
Dr Fonkoua on Alternatives to Platinum Chemotherapy in Cancer Care
August 9th 2023Lionel A. Kankeu Fonkoua, MD, discusses challenges arising from the ongoing shortage of platinum chemotherapy in the United States and suggests potential alternatives to cisplatin that may benefit patients with cancer during this shortage.
Collaboration Is Needed to Address Existing Disparities in Cancer Clinical Trials
Lionel Kankeu Fonkoua, MD, discusses the need for diverse representation across cancer clinical trials and research, emphasizes some of the disparities in enrollment criteria for these research efforts, and details some of the planned and ongoing initiatives at the Mayo Clinic that seek to facilitate change in the field.
2L Dosing Considerations and Management Strategies for SCLC
Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
LAGOON and IMFORTE Trials: Data Updates and Expert Insights
A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.